Lilly moves into hearing loss via Audion investment
By Cormac Sheridan
Monday, February 10, 2014
Eli Lilly and Co. entered the hearing loss field, by investing in a Series A round at Audion Therapeutics BV and supplying a series of compounds, including its γ-secretase inhibitors, to test their potential in hair cell regeneration.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.